Zacks Investment Research upgraded shares of Hookipa Pharma (NASDAQ:HOOK) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $13.00 price objective on the stock.
According to Zacks, “HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company. It is engaged in developing a class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform which is designed to reprogram the body’s immune system. HOOKIPA Pharma Inc. is based in New York, United States. “
Other equities analysts have also recently issued reports about the company. HC Wainwright reaffirmed a buy rating and issued a $15.00 target price on shares of Hookipa Pharma in a report on Friday, January 10th. ValuEngine lowered Hookipa Pharma from a buy rating to a hold rating in a report on Friday, December 27th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Hookipa Pharma currently has an average rating of Buy and an average price target of $18.00.
Shares of Hookipa Pharma stock traded up $0.31 during trading hours on Wednesday, reaching $11.47. 17,745 shares of the stock traded hands, compared to its average volume of 165,591. Hookipa Pharma has a one year low of $6.06 and a one year high of $14.76. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.08. The company has a 50 day moving average price of $10.30 and a 200 day moving average price of $8.25.
Hookipa Pharma (NASDAQ:HOOK) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.21. The business had revenue of $2.04 million during the quarter, compared to the consensus estimate of $2.35 million. Analysts predict that Hookipa Pharma will post -2.12 EPS for the current year.
In other Hookipa Pharma news, insider Igor Matushansky sold 11,484 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $7.87, for a total value of $90,379.08. Following the completion of the transaction, the insider now directly owns 54,895 shares in the company, valued at $432,023.65. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Redmile Group LLC boosted its stake in Hookipa Pharma by 0.3% in the 3rd quarter. Redmile Group LLC now owns 1,897,721 shares of the company’s stock worth $14,233,000 after purchasing an additional 5,842 shares during the period. First Trust Advisors LP purchased a new stake in Hookipa Pharma in the 3rd quarter worth $103,000. Hillhouse Capital Advisors LTD. purchased a new stake in Hookipa Pharma in the 2nd quarter worth $1,923,000. Hillhouse Capital Management LTD. bought a new position in shares of Hookipa Pharma during the 2nd quarter valued at about $4,425,000. Finally, Morgan Stanley bought a new position in shares of Hookipa Pharma during the 2nd quarter valued at about $99,000. 30.71% of the stock is currently owned by institutional investors.
About Hookipa Pharma
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Featured Story: What is the outlook for the FAANG stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.